Patent assignee · US · COMPANY

Unity Biotechnology, Inc.

🏢 View company profile →
41Patents
41Active
41Granted
56Portfolio score

Filing activity: Dec 3, 2013 → Aug 7, 2023

Most-cited patents

PatentTitleAreaCited byStatus
US9849128B2 Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells Chemistry; Metallurgy 23 Active
US10010546B2 Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Chemistry; Metallurgy 19 Active
US10195213B2 Chemical entities that kill senescent cells for use in treating age-related disease Human Necessities 13 Active
US9855266B2 Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline Chemistry; Metallurgy 11 Active
US9993472B2 Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 Chemistry; Metallurgy 9 Active
US10328073B2 Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells Chemistry; Metallurgy 6 Active
US9980962B2 Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease Chemistry; Metallurgy 6 Active
US10258618B2 Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen Chemistry; Metallurgy 5 Active
US10328058B2 Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques Chemistry; Metallurgy 5 Active
US10413542B2 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase Chemistry; Metallurgy 4 Active
US10478432B2 Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye Chemistry; Metallurgy 4 Active
US10213426B2 Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population Chemistry; Metallurgy 4 Active
US10130628B2 Treatment of joint pain Chemistry; Metallurgy 3 Active
US10478433B2 Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss Chemistry; Metallurgy 3 Active
US10517866B2 Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor Chemistry; Metallurgy 3 Active
US10588916B2 Technology to inhibit vascular changes that lead to vision loss in the eye Human Necessities 2 Active
US9988368B1 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use Chemistry; Metallurgy 1 Active
US9969776B2 Drug conjugates for delivering compounds to senescent cells Physics 1 Active
US10717722B2 Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Chemistry; Metallurgy 1 Active
US11351167B2 Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue Chemistry; Metallurgy 1 Active
US10279018B2 Immunogenic compositions for inducing an immune response for elimination of senescent cells Chemistry; Metallurgy 1 Active
US11129838B2 Methods of inhibiting pathological angiogenesis Human Necessities 1 Active
US10981892B2 Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Chemistry; Metallurgy 1 Active
US10519197B1 Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer Human Necessities 1 Active
US10745445B2 Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells Physics 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.